Program


11:00 am	Registration desk opens
3:00-3:05 pm	Welcoming Frederick Hayden
3:05-3:50 pm	Keynote Speaker: Pathogenesis of Zoonotic Respiratory Viral Infections: Studies in SARS and Avian Influenza Malik Peiris, University of Hong Kong
Session I: Epidemiology/Impact
Chair: Robert Webster, St. Jude Children's Research Hospital and Director, World Health Organization Collaborating Center for Studies on the Ecology of Influenza, Memphis, Tennessee
3:50-4:20 pm	The New Respiratory Viruses - Update on Boca Maria Soderlund, Venermo, Haartman Institute, University of Helsinki, Finland
4:20-5:00 pm	Update on Corona NL63 and HKU1 Lia van der Hoek, University of Amsterdam, The Netherlands and Patrick Woo, University of Hong Kong, Pokfulam, Hong Kong SAR, China
5:00-5:30 pm	Evolution and Prevalence of Avian Influenza Viruses in Southern China Yi Guan, The University of Hong Kong, Pokfulam, Hong Kong SAR, China
5:30-6:00 pm	COFFEE BREAK Sponsored by The Macrae Group
6:00-6:15 pm	Epidemiology of Respiratory Viruses: a Hospitalbased Cohort Study Laurent Kaiser, University Hospitals of Geneva, Switzerland
6:15-6:30 pm	Viral Community-Acquired Pneumonia in Adults: the Role of PCR Lance C. Jennings, Canterbury Health Laboratories, Christchurch, New Zealand)
6:30-7:00 pm	Poster Review Albert Osterhaus, Erasmus MC, Rotterdam, The Netherlands
7:00-9:00 pm	Welcoming Reception Sponsored by F. Hoffman-La Roche Ltd.

top of page


7:00-8:00 am	CONTINENTAL BREAKFAST
Session II: Minisymposium on Pandemic Influenza
Chair: Malik Peiris, University of Hong Kong
8:00-8:30 am	Current Animal H5 Situation Robert Webster, St. Jude Children's Research Hospital and Director, World Health Organization Collaborating Center for Studies on the Ecology of Influenza, Memphis, Tennessee
8:30-9:00 am	Use of Vaccination in Asia for H5N1 HAI in Poultry Les Sims, Asia Pacific Veterinary Information Services. Queensland, Australia
9:00-9:30 am	Novel Approaches to Human H5 Vaccine Development Nancy Cox, Atlanta, Georgia, CDC
9:30-9:45 am	Comparison of the Effectiveness of Oseltamivir and Zanamivir against Influenca A Infection in Children Norio Sugaya, Keiyu Hospital, Yokohama, Kanagawa, Japan
9:45-10:00 am	Reduced Pathogenicity and Transmissibility of an Oseltamivir Resistant Influenca Virus A (H3N2)Isolate (N294S) John Oxford, Retroscreen Virology Ltd., London, United Kingdom
10:00-10:45 am	Pandemic Panel Q&A
10:45-11:15 am	COFFEE BREAK Sponsored by The Macrae Group
Session III: Virology and Diagnostics
Chair: Menno de Jong, Oxford University Clinical Research Unit, Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam
11:15-12:00 pm	Non-Pathogen Specific Diagnostics David Relman, Stanford University, California, USA
12:00-12:15 pm	New Unrecognized Human Rhinoviruses are Common Causes of Respiratory Illnesses in Infants Wai-Ming Lee, University of Wisconsin, Madison, Wisconsin, United States
12:15-12:30 pm	Are We Using the Right Cells? Studies of Respiratory Viruses with an In vitro Model of Well-differentiated Airway Epithelia Liqun Zhang, University of North Carolina, Chapel Hill, North Carolina, United States
12:30-3:30 pm	MID-DAY BREAK
3:30-4:00 pm	H5 Diagnostics- Advances Toward POC Detection Menno de Jong, Hospital for Tropical Disease, Ho Chi Minh City, Vietnam
4:00-4:15 pm	The Antigenic and Genetic Evolution of Equine Influenza Virus (H3N8) from 1963 to 2006 Nicola Lewis, University of Cambridge, Kentford, United Kingdom
Session IV: Pathogenesis
Chair: Sebastian Johnston, National Heart & Lung Institute, Imperial College, London, United Kingdom
4:15-5:00 pm	Innate Antiviral Immunity: Friend or Foe in the Lung? Sebastian Johnston, National Heart & Lung Institute, Imperial College, London, UK
5:00-5:30 pm	Pathophysiology of RSV in Infants Robert Welliver, Women and Children™s Hospital, Buffalo, New York, USA
5:30-6:00 pm	Pre-Clinical Papers Literature Review Malik Peiris, Univ of Hong Kong
6:00-6:30 pm	COFFEE BREAK Sponsored by The Macrae Group
6:30-6:45 pm	Young Investigator Award Recipient: Major Group Rhinovirus Induces Airway Inflammation and Anti-viral Immune Responses in Transgenic Mice Expressing Human ICAM-1 Nathan W. Bartlett, National Heart and Lung Institute, Imperial College, London, United Kingdom
6:45-7:00 pm	The RNA Helicases RIG-1 and MDA-5 have a Central Role in Anti-viral Responses to Rhinovirus Michael R. Edwards, National Heart and Lung Institute, Imperial College, London, United Kingdom
7:00-7:15 pm	Young Investigator Award Recipient: Hypercytokinemia in Severe Human Influenza A Infections Nelson Lee, The Chinese University of Hong Kong, Sha Tin, N.T., Hong Kong SAR, China
7:15-7:45 pm	Rhinovirus Infections in Children: How Important Are They? James Gern, University of Wisconsin, Madision, Wisconsin, USA
7:45-9:00 pm	Poster Session Wine & Cheese Reception Sponsored by Novartis Vaccines

top of page


7:30-8:30 am	CONTINENTAL BREAKFAST
Session V: Clinical
Chair: John DeVincenzo, University of Tennessee, Memphis, Tennessee, United States
8:30-9:00 am	Role of Enteroviruses in Respiratory Illness Terho Heikkinen, Turku University Hospital, Turku, Finland
9:00-9:30 am	Adenovirus Disease in Transplant Mike Ison, Northwestern University, Evanston, Illinois, USA
9:30-9:45 am	Transmission of Rhinoviruses in Families with Children Ville Peltola, Turku University Hospital, Finland
9:45-10:00 am	Heterologous Cell-mediated Immunity Priming Using Adjuvanted H5N1 Candidate Vaccine Martine J. Denis, GlaxoSmithKline Biologicals, Rixensart, Belgium
10:00-10:30 am	Literature Review: Clinical Papers Terho Heikkinen, Turku University Hospital, Turku, Finland
10:30-11:00 am	COFFEE BREAK Sponsored by GlaxoSmithKline
Session VI: Vaccinology and Prevention
Chair: Albert Osterhaus, Erasmus MC, Rotterdam, The Netherlands
11:00-11:45 am	Adjuvant Strategies and Flu Vaccines Albert Osterhaus, Erasmus MC, Rotterdam, The Netherlands
11:45-12:00 pm	Young Investigator Award Recipient: Modified Virus-like Particles for the Delivery of a Conserved Influenza Virus-Specific CTL Epitope Wan-Shoo Cheong, Monash University, Victoria, Australia
12:00-12:15 pm	Safety and Immunogenicity of a Cell Culture (Vero) Derived Whole Virus H5N1 Vaccine: A Phase I/II Dose Escalation Study Noel Barrett, Baxter AG, Orth/Donau, Austria
12:15-12:30 pm	Young Investigator Award Recipient: Pandemic Influenza Preparedness: Cross-Reactive Immunity with an Adjuvanted H5N1 Candidate Vaccine Isabel Leroux- Roels, Ghent University and Hospital, Ghent, Belgium
12:30-3:30 pm	MID-DAY BREAK
3:30-4:15 pm	Advances in Pandemic and Seasonal Influenza Vaccines Klaus Stohr, WHO, Geneva, Switzerland
4:15-4:45 pm	Age Difference in Immune Responses: Pediatric Focus Ruth Karron, Johns Hopkins University, Baltimore, Maryland, USA
4:45-5:15 pm	Age Difference in Immune Response: Geriatric Focus Janet McElhaney, University of Connecticut, Storrs, Connecticut
5:15-5:45 pm	Numax Update Jim Young, MedImmune Inc., Gaithersburg, Maryland, USA
5:45-6:15 pm	COFFEE BREAK Sponsored by The Macrae Group
6:15-6:30 pm	Cluster Randomised Household Study of Mask Use in Control of Respiratory Virus Transmission during the Australian Winter of 2006 Raina MacIntyre, University of Sydney, Westmead, New South Wales, Australia
6:30-6:45 pm	Combination Adjuvants for the Induction of Potent, Long-lasting Antibody and T cell Responses to Influenza Vaccines Andreas Wack, Novartis Vaccines, Siena, Italy
6:45-7:00 pm	Immunization with low dose Adjuvanted Split H5N1 Pandemic Vaccine Protects Ferrets Against Homologous and Heterologous Challenges Benoit Baras, GlaxoSmithKline Biologicals, Rixensart, Belgium
7:00-7:15 pm	Immunogenicity and protective Efficacy of a Novel Polycationic Sphingolipid (CCS)-based Liposomal Intramuscular Influenza Vaccine in the Ferret Experimental Model Robert Lambkin- Williams, Retroscreen Virology Ltd, London, United Kingdom
8:00 pm	Special Lecture: Vaccination, Diagnosis, Treatment and Prophylaxis of Seasonal Influenza Nancy Cox, CDC, Atlanta, Georgia, USA
8:30 pm	DINNER Sponsored by Gilead Sciences

top of page


7:30-8:30 am	CONTINENTAL BREAKFAST
Session VI: Vaccinology and Prevention (continued)
8:30-9:00 am	Passive Immunal Therapy for H5 Disease Menno de Jong, Centre for Tropical Disease, Ho Chi Minh City, Vietnam
Session VII: Antivirals and Therapeutics
Chair: Frederick Hayden, GIP/EPR/CDS, World Health Organization, Geneva, Switzerland
9:00-9:45 am	Novel Anti-influenza Agents Frederick Hayden, GIP/EPR/CDS, World Health Organization, Geneva, Switzerland
9:45-10:15 am	Effects of Leukotriene Antagonists on Virus-Induced Wheezing Robert Welliver, Women and Children' Hospital, Buffalo, New York, USA
10:15-10:45 am	Update on siRNA for Respiratory Viruses John DeVincenzo, University of Tennessee, Memphis, USA
10:45-11:15 am	COFFEE BREAK Sponsored by The Macrae Group
11:15-11:30 am	The Emergence of Adamantane Resistance in Influenza A(H1) Viruses in Australia and Regionally in 2006 Ian Barr, WHO Collaborating Centre for Influenza, Parkville, Melbourne, Australia
11:30-11:45 am	In vivo Virus-inhibitory Effects of T-705 Against Influenza A and B Virus Strains<br> Donald F. Smee, Utah State University, Logan, Utah, United States
11:45-12:00 pm	Development of DAS181 as a Broad-spectrum Treatment for Influenza Fang Fang, NexBio Inc., San Diego, California, United States
12:00-12:15 pm	A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and efficacy of RSV604 in Adults with Respiratory Syncytial Virus (RSV) Infection Following Stem Cell Transplantation Francisco Marty, Brigham & Women’s Hospital, Dana Farber Institute, Boston, Massachusetts, United States
12:15-12:30 pm	Wrap Up and Concluding Remarks Robert Webster & Frederick Hayden
12:30-1:00 pm	Closed Panel

top of page